Drugs that contain Ethinyl Estradiol; Levonorgestrel
1. Balcoltra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6716814 | AVION PHARMS | Enhancing solubility of iron amino acid chelates and iron proteinates |
Aug, 2021
(2 years ago) | |
| US7838042 | AVION PHARMS | Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions |
Jun, 2027
(3 years from now) | |
Market Authorisation Date: 09 January, 2018
Treatment: Administration of ferrous bisglycinate tablets
Dosage: TABLET;ORAL
BALCOLTRA family patents
2. Loseasonique patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7615545 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(10 months ago) | |
| US7858605 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(9 months ago) | |
| US7855190 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 24, 2011 |
Market Authorisation Date: 24 October, 2008
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
LOSEASONIQUE family patents
3. Lybrel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6500814 | WYETH PHARMS INC | Hormonal contraceptive |
Sep, 2018
(5 years ago) | |
Market Authorisation Date: 22 May, 2007
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
LYBREL family patents
4. Preven Emergency Contraceptive Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6156742 | TEVA BRANDED PHARM | Emergency contraceptive kit |
Dec, 2020
(3 years ago) | |
Market Authorisation Date: 01 September, 1998
Treatment: Kit adapted and designed to provide both data on the current reproductive status of a patient and contraception for those who are not pregnant, but recently engaged in unprotected sex
Dosage: TABLET;ORAL
PREVEN EMERGENCY CONTRACEPTIVE KIT family patents
5. Quartette patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8450299 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
Oct, 2025
(1 year, 5 months from now) | |
| US8415332 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
Mar, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2016 |
Market Authorisation Date: 28 March, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
QUARTETTE family patents
6. Seasonale patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE39861 | TEVA BRANDED PHARM | Methods of extended use oral contraception |
Jun, 2017
(6 years ago) | |
| US5898032 | TEVA BRANDED PHARM | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
Jun, 2017
(6 years ago) | |
Market Authorisation Date: 05 September, 2003
Treatment: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception; Prevention of pregnancy
Dosage: TABLET;ORAL
SEASONALE family patents
7. Seasonique patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7615545 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(10 months ago) | |
| US7858605 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jun, 2023
(9 months ago) | |
| US7320969 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jan, 2024
(2 months ago) | |
| US7855190 | TEVA BRANDED PHARM | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
Dec, 2028
(4 years from now) | |
Market Authorisation Date: 25 May, 2006
Treatment: Prevention of pregnancy; Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET;ORAL
SEASONIQUE family patents
8. Twirla patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8883196 | AGILE | Transdermal hormone delivery system: compositions and methods |
Nov, 2020
(3 years ago) | |
| US8221785 | AGILE | Transdermal hormone delivery system: compositions and methods |
Mar, 2021
(3 years ago) | |
| US7045145 | AGILE | Transdermal contraceptive delivery system and process |
Mar, 2021
(3 years ago) | |
| US7384650 | AGILE | Skin permeation enhancement composition for transdermal hormone delivery system |
Mar, 2021
(3 years ago) | |
| US8221784 | AGILE | Transdermal hormone delivery system: compositions and methods |
Mar, 2021
(3 years ago) | |
| US9050348 | AGILE | Dermal delivery device |
Jul, 2028
(4 years from now) | |
| US8747888 | AGILE | Dermal delivery device with in situ seal |
Jul, 2028
(4 years from now) | |
| US8246978 | AGILE | Dermal delivery device with reduced loss of its volatile components |
Aug, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 14, 2023 |
Market Authorisation Date: 14 February, 2020
Treatment: A transdermal method of contraception
Dosage: SYSTEM;TRANSDERMAL
TWIRLA family patents